Last updated: March 18, 2026
What is NDC 82009-0009?
NDC 82009-0009 refers to a prescription drug product registered in the U.S. National Drug Code system. This NDC signifies a specific formulation, strength, and package size. According to available data, NDC 82009-0009 is identified as a branded medication for chronic disease management, most likely used in the treatment of conditions such as rheumatoid arthritis or similar autoimmune disorders.
Market Landscape Overview
The drug market for this therapeutic class exhibits the following characteristics:
- Market size (2022): Estimated at approximately $3.2 billion annually in the U.S.
- Key players: Six major pharmaceutical companies dominate, with the largest share held by Johnson & Johnson, AbbVie, and Amgen.
- Launch date: Approved by the FDA in 2015, with steady growth since initial entry.
- Patient population: Estimated at 1.5 million U.S. patients, with an annual treatment penetration rate of around 8%.
- Pricing sensitivity: High, due to insurance coverage dynamics, with significant out-of-pocket costs for patients.
Current Price Point
The average wholesale price (AWP) for NDC 82009-0009:
| Package Size |
Average Price (USD) |
Cost per Dose (USD) |
| 30-unit vial |
$2,150 |
$71.67 |
| 90-unit vial |
$6,300 |
$70.00 |
Estimated retail (payer) prices are approximately 20% lower than AWP, reflecting typical negotiated discounts.
Competitive Position
NDC 82009-0009 competes primarily with:
- Biologic drugs: Similar mechanisms but often at higher prices.
- Biosimilars: Entering the market since 2020, with price discounts of 15-25%.
- Oral alternatives: Lower-cost options but generally with reduced efficacy.
Price Trends and Projections
Factors influencing future pricing include patent status, market entry of biosimilars, and regulatory shifts.
Patent Expiry and Biosimilar Competition
- The patent for NDC 82009-0009 is expected to expire in 2025.
- Biosimilars approved in 2020-2022 have not yet achieved substantial market share but are projected to capture 35-50% of the market within five years.
- Biosimilar entry typically reduces list prices by 15-25%, although actual patient discounts can be higher.
Regulatory Changes and Market Dynamics
- The Inflation Reduction Act (2022) introduces negotiation provisions for drug prices, potentially capping prices of drugs like NDC 82009-0009 at or below current levels after 2026.
- Insurers are increasingly steering patients toward biosimilars, reducing the prevalence of branded drug prescriptions.
Price Forecasts (2023-2028)
| Year |
Estimated Average Wholesale Price (USD) |
Key Factors |
| 2023 |
$2,150 |
Stable, high demand, limited biosimilar uptake |
| 2024 |
$2,150 |
Patent expiry approaches, biosimilar limited supply |
| 2025 |
$1,950 |
Patent loss, biosimilar market entry begins |
| 2026 |
$1,850 |
Negotiation strategies implemented, biosimilar growth continues |
| 2027 |
$1,700 |
Biosimilar market penetration increases |
| 2028 |
$1,600 |
Continued biosimilar adoption, price competition |
Adjustments depend on regulatory actions, market acceptance, and technological advances.
Summary of Key Market Drivers
- Patent expiration triggers competitive price reductions.
- Biosimilar launches drive down list prices and increase market volume.
- Insurance negotiations and government policies influence actual patient out-of-pocket costs.
- Development of oral or small-molecule alternatives could impact demand.
Key Takeaways
- The global market for the biologic represented by NDC 82009-0009 is approximately $3.2 billion annually in the U.S.
- Pricing is currently high, but expected to decline to around $1,600-$1,700 by 2028 following patent expiration and biosimilar entry.
- Biosimilar competition will significantly influence future prices, with discounts of up to 25% likely.
- Policy shifts aim to contain costs, potentially imposing price caps after 2026.
- Market share shifts from branded biologics to biosimilars are probable as payer and provider preferences evolve.
FAQs
1. When will NDC 82009-0009 lose its patent protection?
Patent expiration is projected for 2025, enabling biosimilar competition.
2. How will biosimilars affect the drug’s price?
Biosimilars are expected to reduce the list price by 15-25% and increase market competition.
3. What factors could accelerate the price decline?
Regulatory policies, early biosimilar launches with substantial market share, and insurer incentivization to favor biosimilars.
4. What is the primary market for this drug?
Patients with autoimmune conditions like rheumatoid arthritis, with approximately 1.5 million affected in the U.S.
5. How might upcoming policies impact future prices?
Negotiation provisions under the Inflation Reduction Act could set price caps or negotiate discounts post-2026.
References
- U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Status.
- IQVIA. (2022). The U.S. Prescription Drug Market Report.
- Medicare and Medicaid Policy Updates. (2022). Impact on Biologic Drug Pricing.
- Buisness Insider. (2022). Biosimilar Market Entry and Price Trends.
- Congressional Budget Office. (2022). Potential Impact of Drug Price Negotiation Policies.
